Clinical Trial Update: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. [Phase 1]

View source ↗

Summary

Phase 1 two-part single and multiple ascending dose trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of LBT-3627 in healthy partic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• LBT-3627 (LBT-3627)

Snippet

Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary) | Conditions: Parkinson Disease | Phase 1 | Status: RECRUITING